Ernexa Therapeutics, Inc. (ERNA)
1.88
+0.05
(+2.73%)
USD |
NASDAQ |
Nov 06, 16:00
1.85
-0.03
(-1.60%)
After-Hours: 20:00
Ernexa Therapeutics Cash from Investing (Quarterly) : -0.003M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.003M |
| March 31, 2026 | -0.002M |
| December 31, 2025 | -0.015M |
| September 30, 2025 | -0.022M |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | -0.019M |
| June 30, 2024 | -0.249M |
| March 31, 2024 | -0.097M |
| December 31, 2023 | -0.019M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.129M |
| September 30, 2022 | -0.043M |
| June 30, 2022 | -0.087M |
| March 31, 2022 | -0.046M |
| December 31, 2021 | -0.147M |
| September 30, 2021 | -22.86M |
| June 30, 2021 | -0.001M |
| March 31, 2021 | 0.267M |
| December 31, 2020 | -0.0128M |
| September 30, 2020 | 0.00 |
| June 30, 2020 | -0.0217M |
| Date | Value |
|---|---|
| March 31, 2020 | -0.0045M |
| December 31, 2019 | -0.101M |
| September 30, 2019 | -0.246M |
| June 30, 2019 | -0.322M |
| March 31, 2019 | -0.396M |
| December 31, 2018 | -0.387M |
| September 30, 2018 | -0.488M |
| June 30, 2018 | -0.332M |
| March 31, 2018 | -0.372M |
| December 31, 2017 | -0.334M |
| September 30, 2017 | -0.417M |
| June 30, 2017 | -0.452M |
| March 31, 2017 | -0.249M |
| December 31, 2016 | -0.156M |
| September 30, 2016 | -0.218M |
| June 30, 2016 | -0.19M |
| March 31, 2016 | -0.276M |
| December 31, 2015 | -0.331M |
| September 30, 2015 | -0.477M |
| June 30, 2015 | -0.378M |
| March 31, 2015 | -0.437M |
| December 31, 2014 | -0.525M |
| September 30, 2014 | -0.596M |
| June 30, 2014 | -0.01M |
| March 31, 2014 | -0.77M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Cerenome, Inc. | 5.366M |
| ACADIA Pharmaceuticals, Inc. | -- |
| Alnylam Pharmaceuticals, Inc. | -311.74M |
| Anika Therapeutics, Inc. | -1.28M |
| Savara, Inc. | 32.60M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -4.152M |
| Cash from Financing (Quarterly) | 0.006M |
| Free Cash Flow | -8.878M |
| Free Cash Flow Per Share (Quarterly) | -3.512 |
| Free Cash Flow to Equity (Quarterly) | -4.115M |
| Free Cash Flow to Firm (Quarterly) | -4.155M |
| Free Cash Flow Yield | -721.5% |